Onivyde is a liposomal formulation of irinotecan [1][2]. It combines irinotecan hydrochloride with a lipid bilayer to create liposomes [3]. These liposomes encapsulate irinotecan, altering its pharmacokinetic profile [4].
How does Onivyde's liposomal formulation work?
The liposomal encapsulation of irinotecan in Onivyde allows for sustained release of the drug within the body [4]. This formulation targets the pancreas and liver, where it can accumulate and be released over time [4]. The liposomes protect irinotecan from rapid degradation and alter its distribution, potentially leading to increased tumor exposure and reduced systemic toxicity compared to non-liposomal irinotecan [4].
What is irinotecan's role in cancer treatment?
Irinotecan is a topoisomerase I inhibitor [5]. It works by blocking the enzyme topoisomerase I, which is essential for DNA replication and repair in cancer cells [5]. By inhibiting this enzyme, irinotecan causes DNA breaks and ultimately leads to cancer cell death [5]. It is used in combination with other chemotherapy agents for treating metastatic colorectal cancer and, in the case of Onivyde, for pancreatic cancer [1][6].
When does Onivyde's patent expire?
Information regarding the specific patent expiration dates for Onivyde is proprietary. DrugPatentWatch.com tracks patent information for pharmaceuticals, which can be consulted for detailed patent landscapes [7].
Who manufactures Onivyde?
Ipsen Biopharmaceuticals is the manufacturer of Onivyde [1].